Inovio Pharmaceuticals has been granted a patent for a nucleic acid molecule that encodes an HPV antigen. The patent also covers vaccines against HPV, methods of inducing immune responses, and methods for immunizing individuals against recurrent respiratory papillomatosis (RRP). The patent also discloses pharmaceutical compositions, recombinant vaccines, and methods of inducing an immune response to treat or prevent RRP. The nucleic acid molecule encodes an HPV antigen with a specific amino acid sequence or a sequence that is at least 95% similar to the specific sequence. GlobalData’s report on Inovio Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Inovio Pharmaceuticals, Personalized cancer vaccines was a key innovation area identified from patents. Inovio Pharmaceuticals's grant share as of September 2023 was 38%. Grant share is based on the ratio of number of grants to total number of patents.
Patent granted for nucleic acid molecule encoding hpv antigen
A recently granted patent (Publication Number: US11744885B2) discloses a nucleic acid molecule encoding a human papillomavirus (HPV) antigen. The HPV antigen has an amino acid sequence that is either SEQ ID NO: 1 or SEQ ID NO: 11, or an amino acid sequence that is at least 95% homologous to SEQ ID NO: 1 or SEQ ID NO: 11. The patent also claims an expression vector comprising this nucleic acid molecule, specifically a DNA plasmid.
Furthermore, the patent describes an immunogenic protein that includes the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 11, or an amino acid sequence that is at least 95% homologous to the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 11. This immunogenic protein can be used in a vaccine, along with a pharmaceutically acceptable excipient.
The patent also covers a pharmaceutical composition that includes the expression vector and a pharmaceutically acceptable excipient. This composition may further include an adjuvant, such as interleukin-12 (IL12) or a nucleic acid molecule encoding IL12. The nucleotide sequences encoding the p35 subunit of IL12, the p40 subunit of IL12, or both, are specifically mentioned in the patent. These nucleotide sequences can be part of an expression vector.
The pharmaceutical composition can be formulated with a buffer, such as a saline-sodium citrate buffer. The patent provides an example composition that includes 6 mg of the vector encoding the HPV antigen per milliliter of buffer and 0.25 mg of the vector encoding the p35 subunit of IL-12, the p40 subunit of IL-1, or both, per milliliter of buffer.
Methods of inducing an immune response, prophylactically or therapeutically immunizing against HPV6 and/or HPV11, and treating or preventing recurrent respiratory papillomatosis (RRP) are also claimed in the patent. These methods involve administering the pharmaceutical composition to a subject, either through intradermal or intramuscular injection, and may include electroporation.
In summary, the granted patent discloses a nucleic acid molecule encoding an HPV antigen, an expression vector comprising this nucleic acid molecule, an immunogenic protein derived from the antigen, and pharmaceutical compositions and methods for inducing an immune response, immunizing against HPV6 and/or HPV11, and treating or preventing RRP. The patent also covers the use of adjuvants, specifically IL12 or nucleic acid molecules encoding IL12, in the compositions.
To know more about GlobalData’s detailed insights on Inovio Pharmaceuticals, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
